<DOC>
	<DOCNO>NCT01696084</DOCNO>
	<brief_summary>To confirm efficacy CPX-351 compare 7+3 first line therapy elderly patient ( 60-75 yr ) high risk ( secondary ) Acute Myeloid Leukemia . The primary efficacy endpoint overall survival .</brief_summary>
	<brief_title>Phase III Study CPX-351 Versus 7+3 Patients 60-75 Years Old With Untreated High Risk ( Secondary ) Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand voluntarily give informed consent Age 6075 year time diagnosis AML Pathological diagnosis AML accord WHO criteria ( least 20 % blast peripheral blood bone marrow ) Confirmation : Therapy related AML : tAML must document history prior cytotoxic therapy ionize radiotherapy unrelated disease AML history myelodysplasia : MDSAML must bone marrow documentation prior MDS AML history CMMoL : CMMoLAML must bone marrow documentation prior CMMoL De novo AML karyotypic abnormality characteristic MDS : de novoAML must cytogenetics abnormality per WHO . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Able adhere study visit schedule protocol requirement Laboratory value fulfil follow : Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin &lt; 2.0 mg/dL , patient Gilbert 's Syndrome contact medical monitor Serum alanine aminotransferase aspartate aminotransferase &lt; 3 time ULN Note : If elevate liver enzyme , ULN , related disease ; contact medical monitor discus . Cardiac ejection fraction ≥ 50 % echocardiography MUGA Patients second malignancy remission may eligible clinical evidence disease stability period great 6 month cytotoxic chemotherapy , document imaging , tumor marker study , etc. , screen . Patients maintain longterm nonchemotherapy treatment , e.g. , hormonal therapy , eligible . Except CMMoL , patient history myeloproliferative neoplasm ( MPN ) ( defined history essential thrombocytosis polycythemia vera , idiopathic myelofibrosis prior diagnosis AML ) combine MDS/MPN eligible . Acute promyelocytic leukemia [ ( 15 ; 17 ) ] favorable cytogenetics , include ( 8 ; 21 ) inv16 know time randomization . Clinical evidence active CNS leukemia Patients active ( uncontrolled , metastatic ) second malignancy exclude . Prior treatment intend induction therapy AML ; hydroxyurea permit control blood count . For example , patient MDS change HMA dose schedule diagnosis AML exclude . AMLtype therapy , cytarabine alone ( &gt; 1g/m2/day ) cytarabine plus anthracycline well prior HSCT also exclude . Administration therapy MDS ( conventional investigational ) must complete 2 week prior first dose study drug ; event rapidly proliferative disease use hydroxyurea permit 24 hour start study treatment . Toxicities associate prior MDS therapy must recover grade 1 less prior start treatment . Any major surgery radiation therapy within four week . Patients prior cumulative anthracycline exposure great 368 mg/m2 daunorubicin ( equivalent ) . Any serious medical condition , laboratory abnormality psychiatric illness would prevent obtain informed consent Patients myocardial impairment cause ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) result heart failure New York Heart Association Criteria ( Class III IV stag ) Active uncontrolled infection . Patients infection receive treatment ( antibiotic , antifungal antiviral treatment ) may enter study must afebrile hemodynamically stable ≥72 hr . Current evidence invasive fungal infection ( blood tissue culture ) ; patient recent fungal infection must subsequent negative culture eligible ; know HIV ( new testing require ) evidence active hepatitis B C infection ( rise transaminase value ) Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease coppermetabolism disorder</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>high risk AML</keyword>
	<keyword>secondary AML</keyword>
	<keyword>AML elderly</keyword>
</DOC>